Evidence map›Paper›PMID 26758365›Full record

ArticleCirculation. Heart failure2016

Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.

Emily P Zeitler, Anne S Hellkamp, Phillip J Schulte, Gregg C Fonarow, Adrian F Hernandez, Eric D Peterson, Gillian D Sanders, Clyde W Yancy, Sana M Al-Khatib

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Underrepresentation of women in implantable cardioverter defibrillator trials.American heart journal plus : cardiology research and practice · 2022
    Article
  2. Sex-Specific Outcomes in Cardiovascular Device Evaluations.Journal of women's health (2002) · 2020
    Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Emily P ZeitlerFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Anne S HellkampFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Phillip J SchulteFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Gregg C FonarowFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Adrian F HernandezFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Eric D PetersonFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Gillian D SandersFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Clyde W YancyFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.).
Sana M Al-KhatibFrom the Duke Clinical Research Institute, Durham, NC (E.P.Z., A.S.H., A.F.H., E.D.P., G.D.S., S.M.A.-K.); Department of Medicine, Division of Cardiology, Duke University Hospital, Durham, NC (E.P.Z., A.F.H., E.D.P., S.M.A.-K.); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (P.J.S.); Department of Medicine, Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-University of California, Los Angeles Medical Center (G.C.F.); Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL (C.W.Y.). alkha001@mc.duke.edu.

Funding

Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
Using Data to Drive Change in National CV Care: The Duke CERTSU19HS021092 · AHRQ · DUKE UNIVERSITY · PI PETERSON, ERIC DAVID · 2011 to 2015
$4.2M
AHRQ HHS U19 HS021092AHRQ HHS U19HS021092NHLBI NIH HHS T32 HL069749
6 · The paper itself

Abstract

backgroundClinical trials of implantable cardioverter defibrillators (ICDs) for primary prevention enrolled a limited number of women. We sought to examine clinical practice data to compare survival rates among women with heart failure with or without a primary prevention ICD. METHODS AND

resultsWe linked data from 264 US hospitals included in the Get With The Guidelines for Heart Failure registry with data from the Centers for Medicare and Medicaid Services. From these sources, we propensity score matched 430 women with heart failure who received a primary prevention ICD to 430 women who did not; we further adjusted using a Cox proportional hazards model. Median follow-up was 3.4 and 3.0 years. For comparison, we matched 859 men receiving an ICD with 859 who did not; median follow-up was 3.9 versus 2.9 years. In the matched cohorts, an ICD was associated with similarly better survival in women (hazard ratio, 0.78; 95% confidence interval, 0.66-0.92; P=0.003) and men (hazard ratio, 0.76; 95% confidence interval, 0.67-0.87 P<0.001). There was no interaction between sex and presence of an ICD with respect to survival (P=0.79).

conclusionsAmong patients with heart failure with reduced left ventricular ejection fraction, a primary prevention ICD was associated with a significant survival advantage among women and among men. These findings support guideline-directed use of primary prevention ICDs in eligible patients.

Indexed as

Defibrillators, ImplantableAgedAged, 80 and overCenters for Medicare and Medicaid Services, U.S.Chi-Square DistributionComparative Effectiveness ResearchElectric CountershockFemaleHeart FailureHospitalizationHumansKaplan-Meier EstimateLogistic ModelsMaleMarkov ChainsMonte Carlo Methodcomparative effectiveness researchheart failureimplantable cardioverter-defibrillatorsmorbiditymortalitywomen

Identifiers

PMID26758365
PMCPMC4712727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.